STOCK TITAN

[SCHEDULE 13G] RAPT Therapeutics, Inc. SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

RAPT Therapeutics, Inc. has a Schedule 13G disclosure showing Nantahala Capital Management, LLC and its managing members, Wilmot B. Harkey and Daniel Mack, beneficially own 951,613 shares of RAPT common stock, representing 5.75% of the outstanding class. The filing states these shares are held by funds and separately managed accounts under Nantahala's control and that none of the Reporting Persons possess sole voting or dispositive power; all voting and dispositive power is shared. The statement affirms the position was acquired and is held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: A passive, disclosed 5.75% stake creates ownership visibility without signalling an activist intent.

The Schedule 13G reports a meaningful minority stake—951,613 shares equal to 5.75%—held through Nantahala-managed funds and accounts. Classification as a Schedule 13G filing and the explicit certification that the position is held in the ordinary course and not to influence control indicate a passive investment posture, which typically reduces near-term governance or strategic activism risk. No sole voting or dispositive power is claimed, which limits unilateral influence on corporate decisions.

TL;DR: Disclosure improves transparency; shared control implies limited immediate governance impact.

The filing clearly attributes shared voting and dispositive power to Nantahala and its principals, with each Reporting Person reported as beneficial owner of the same 951,613 shares. Filing under Schedule 13G and the accompanying certification signals compliance with passive-investor treatment under SEC rules. From a governance viewpoint, the reported ownership size is material enough to warrant attention by management and investors but, given the declared passive intent and lack of sole control, it does not by itself indicate impending governance action.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Nantahala Capital Management, LLC
Signature:/s/ Taki Vasilakis
Name/Title:Taki Vasilakis / Chief Compliance Officer
Date:08/14/2025
Wilmot B. Harkey
Signature:/s/ Wilmot B. Harkey
Name/Title:Wilmot B. Harkey
Date:08/14/2025
Daniel Mack
Signature:/s/ Daniel Mack
Name/Title:Daniel Mack
Date:08/14/2025
Rapt Therapeutics, Inc.

NASDAQ:RAPT

View RAPT Stock Overview

RAPT Rankings

RAPT Latest News

RAPT Latest SEC Filings

RAPT Stock Data

1.68B
23.85M
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO